Abstract
Seizure is a recognized complication of high-dose busulfan (BU) therapy and phenytoin (DPH) is widely used as prophylaxis. A number of adverse effects have been associated with DPH and it may also interfere with BU metabolism. We used lorazepam (median dose 0.022 mg/kg) i.v. or p.o. before each dose and for 24 h after the last dose of BU as seizure prophylaxis to 29 children undergoing hematopoietic stem cell transplantation. The regimen was well tolerated and drowsiness was the only significant side-effect. Twelve patients were able to receive the entire prophylaxis by mouth. No seizure developed during and within 48 h of BU. Concomitant pharmacokinetic studies showed no alternation of the absorption and clearance of BU during lorazepam administration. Lorazepam can be used as an alternative for seizure prophylaxis during high-dose BU treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Vassal G, Gouyette A, Hartmann O et al. Pharmacokinetics of high-dose busulfan in children Cancer Chemother Pharmacol 1989 24: 386 390
Santos GW . Busulfan and cyclophosphamide for marrow transplantation Bone Marrow Transplant 1989 4: (Suppl. 1) 236
Vassal G, Deroussent A, Hartmann O et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study Cancer Res 1990 50: 6203 6207
Hassan M, Oberg G, Bjorkholm M et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics Cancer Chemother Pharmacol 1993 33: 181 186
Grigg AP, Shepherd JD, Phillips GL . Busulphan and phenytoin Ann Int Med 1989 111: 1049 1050
De La Camara R, Tomas JF, Figuera A et al. High-dose busulfan and seizures Bone Marrow Transplant 1991 7: 363 364
Tiberghien P, Flesch M, Paintaud G et al. More on high-dose busulfan and seizure prophylaxis Bone Marrow Transplant 1992 9: 147 149
Shaw PJ, Scharping CE, Brian RJ et al. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia Blood 1994 84: 2357 2362
Schwarer AP, Opat SS, Watson AL et al. Clobazam for seizure prophylaxis during busulfan chemotherpay Lancet 1995 346: 1248
Tran HT, Madden T, Petropoulos D et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies BoneMarrow Transplant 2000 26: 463 470
Prezepiorka D, Khouri I, Ippoliti C et al. Tacrolimus and minidose methotrexate for the prevention of acute graft-versus-host disease after HLA-mismatched marrow and blood stem cell transplantation Bone Marrow Transplant 1999 24: 763 768
Hughes-Jones K, Shaw PJ . No convulsions in children in high-dose busulphan Lancet 1985 1: 220
Fitzsimmons W, Ghalie R, Kaizer H . Anticonvulsants and busulfan Ann Intern Med 1990 112: 552 553
Neef C, De Voogd-van der Straaten I . An interaction between cytostatic and anticonvulsant drugs Clin Pharmacol Ther 1988 43: 372 375
Meloni G, Nasta L, Pinto RM et al. Clonazepam prophylaxis and busulfan-related myoclonic epilepsy in autografted acute leukemia patients Haematologica 1995 80: 532 534
Van Hoff J, Olszewski D . Lorazepam for the control of chemotherapy-induced nausea and vomiting in children J Pediatr 1988 113: 146 149
Giang DW, McBride MC . Lorazepam versus diazepam for the treatment of status epilepticus Pediatr Neurol 1998 4: 358 361
Hassan M, Ehrsson H, Wallin I et al. Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain Eur J Drug Metab Pharmacokinet 1988 13: 301 305
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chan, K., Mullen, C., Worth, L. et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant 29, 963–965 (2002). https://doi.org/10.1038/sj.bmt.1703593
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703593
Keywords
This article is cited by
-
Comparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantation
International Journal of Hematology (2019)
-
Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation
International Journal of Hematology (2016)
-
Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan
International Journal of Clinical Pharmacy (2013)
-
Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen
Bone Marrow Transplantation (2010)
-
Neurologic Complications of Cancer and its Treatment
Current Oncology Reports (2010)